Desloratadine

Drugs

Volumn 61, Issue 6, 2001, Pages 789-796

  McClellan, K ^a   Jarvis, B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOCHROME P450 INHIBITOR; DESLORATADINE; PLACEBO;

ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHRONIC URTICARIA; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; HEADACHE; HUMAN; PHARYNGITIS; PSYCHOMOTOR ACTIVITY; QUALITY OF LIFE; SLEEP PATTERN; XEROSTOMIA;

ANIMALIA;

EID: 0034984381     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161060-00007     Document Type: Article

References (39)

1. Therapeutic advantages of third generation antihistamines
2. 1-receptor antagonists: Comparative tolerability and safety
3. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine
4. Second-generation antihistamines: The risk of ventricular arrhythmias
5. 1 receptor antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects
6. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells
7. Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured bronchial epithelial cells
8. + cells
9. 1-antagonist, desethoxycarbonyl-loratadine
10. 1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines
11. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis
12. 1 receptor antagonist. 2nd communication: Lack of central nervous system and cardiovascular effects
13. Electrocardiographic effects of multiple high doses of desloratadine
14. Lack of electrocardiographic effects of multiple high doses of desloratadine
15. Dosloratadine has no effect on wakefulness or psychomotor performance
16. Desloratadine does not impair actual driving performance: A 3-way crossover comparison with diphenhydramine and placebo
17. Dose-proportionality, linearity, and pharmacokinetics of desloratadine in healthy adults
18. The effect of food on the oral bioavailability of desloratadine
19. Multiple-dose pharmacokinetics, safety, and tolerance of desloratadine in healthy volunteers
20. Multiple-dose pharmacokinetics of desloratadine in subjects differing in race and gender
21. Desloratadine and ketoconazole: Pharmacokinetics and electrocardiographic pharmacodynamic effects
22. Effects of various cytochrome P450 inhibitors on the clearance of loratadine (L)/descarboethoxyloratadine (DCL) and lack of effects of increased L and DCL plasma concentrations on QTc intervals
23. Desloratadine and erythromycin: Pharmacokinetics and electrocardiographic pharmacodynamic effects
24. No drug interaction between fluoxetine and desloratadine, a new nonsedating once-daily antihistamine
25. Effect of desloratadine on p-glycoprotein transport system (MDRI)
26. Unlike fexofenadine, the pharrnacokinetics of desloratadine are minimally altered by coadministration with azithromycin
27. max and AUC of fexofenadine by 30%
28. Desloratadine and alcohol coadministration: No increase in impairment of performance over that induced by alcohol alone
29. 1-receptor antagonist, in patients with seasonal allergic rhinitis: Assessment during the spring and fall allergy seasons
30. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study
31. Desloratadine has an early onset of action and long-term benefit for SAR symptoms
32. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis
33. Desloratadine relieved nasal congestion in patients with seasonal allergic rhinitis and concurrent asthma
34. Quality of life in patients with seasonal allergic rhinitis is improved by desloratadine
35. Health-related quality of life outcomes of desloratadine in patients with moderate-to-severe SAR
36. 2-agonists and improves asthma symptoms in patients with seasonal allergic rhinitis and asthma
37. Long-term benefit of desloratadine against seasonal allergic rhinitis symptoms in patients with asthma
38. Desloratadine reduces seasonal allergic rhinitis symptoms in patients with seasonal allergic rhinitis and asthma
39. Desloratadine improved SAR symptoms in patients with mild to moderate asthma and SAR